(Press-News.org) (WASHINGTON, May 9, 2024) – Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.
AML is an aggressive and often deadly form of blood cancer that can be difficult to treat. For older adults with AML, the conventional treatment consists of a medication called venetoclax combined with a hypomethylating agent (HMA), also known as VEN-HMA. AML treatment is often intensive and can significantly suppress the immune system and put one at risk of other health complications. As a result, some adults with AML, especially those of advanced older age, may be considered ineligible to receive treatment at all and be recommended to pursue palliative care.
“Our study reveals that a significant portion of these patients at the extremes of older age still derive benefit from the VEN-HMA regimen – which is the standard of care for older AML patients and those who are ineligible to receive intensive chemotherapy. While acknowledging it certainly isn’t for everyone, we hope our findings encourage health care providers to thoughtfully explore all treatment avenues for elderly patients with AML, rather than prematurely resorting to HMA alone, best supportive care, or hospice care,” said Justin Watts, MD, a hematologist at the University of Miami Sylvester Comprehensive Cancer Center, in Miami, Florida, and the study’s corresponding author.
Researchers sought to understand overall survival and remission rates among octo- and nonagenarians (those 80-90 and older) who received VEN-HMA treatment to determine its effectiveness. They analyzed electronic medical records from 154 patients with AML treated with VEN-HMA for the first time between March of 2015 and April of 2022 across six medical institutions in the United States and Italy. Participants had a median age of 82 (range 80-92) and 69% were male. Seventy-seven percent of patients included in the study were newly diagnosed, 10% had relapsed or refractory AML, and for 14%, disease status was unknown.
Sixty-seven percent of patients started treatment with the standard dose and treatment schedule of VEN-HMA, and 72% of the cohort had subsequent modifications of their venetoclax dose or schedule after cycle 1 (e.g., reduction in venetoclax duration). Across the cohort, patients were administered a final median venetoclax dose of 400 mg for 21 days, repeated every 35 days. Patients who demonstrated a response to treatment received a final median venetoclax dose of 200mg of Venetoclax for 21 days, in 35-day cycles.
Approximately 20 to 25% of all treated patients experienced prolonged survival, which encompassed roughly 40% of those who responded to treatment. Median overall survival was 8.1 months, and for those who responded to treatment, it was 13.2 months. At just under eight months follow-up, 23% of patients remained in remission, while 20% were still receiving treatment. Death rates within 30 and 60 days of treatment were 8.5% and 17%, respectively, comparable to VIALE-A.
For patients with newly diagnosed AML without a prior myelodysplastic syndrome (MDS), 73% achieved complete remission or complete remission with incomplete count recovery (CRc), a classification given when a patient’s leukemia cell counts are undetectable, but blood cell counts have not fully returned to normal levels. For patients who achieved CRc, those who received a final venetoclax duration of 14 days or less per cycle had a better average survival time (median of 24.0 months).
Patients whose cancer cells had a mutation in TP53 – a protein vital to preventing abnormal cell growth – exhibited poorer overall survival. Patients with a mutation in the NPM1 protein had very favorable survival, and, interestingly, patients with K/NRAS or FLT3-ITD mutations did not have inferior survival compared to those without.
Notably, this treatment regimen can lead to myelosuppression, reducing the bone marrow’s ability to produce healthy blood cells and weakening the immune system. Older patients, especially those over 80, may be more vulnerable to experiencing myelosuppression, and because of this, researchers suggest reducing the dose and duration of treatment for those at increased risk. “A second major theme here is that treating this patient population requires adjusting the dosage and duration of VEN-HMA," explained Dr. Watts. "Unlike typical adult AML cases, these patients exhibit lower tolerance to Venetoclax, suggesting that they may benefit from a reduced dosage.”
This study is limited by its retrospective format. Further, the median follow-up duration was approximately 7.7 months, and researchers acknowledge their data may have been stronger if this was extended.
Researchers said they plan to study the optimal dose and treatment schedule for this population to further enhance health outcomes. They want to explore the relationship between minimal residual disease (MRD) and molecular subtype on venetoclax exposure and ultimately stopping venetoclax in a subset of durably responding patients. Researchers said they are also interested in developing a better understanding of how treatment affects quality of life.
# # #
Blood Neoplasia (www.bloodneoplasia.org) is an online only, open access journal of the American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders.
Blood Neoplasia® is a registered trademark of the American Society of Hematology.
END
INDIANAPOLIS -- Neighborhoods of high need are where investment in social care offers the best opportunities to improve health. Screening for social determinants of health is comparatively easy, but building the infrastructure to meet needs occurring outside the formal healthcare system is quite difficult. Few health systems have achieved more than even partial integration of social care into routine patient care.
In a case study of pioneering social care provided by Eskenazi Health, a safety net health system located in Indianapolis, ...
Australian researchers have discovered how changes in antibody levels over time can predict which children are likely to outgrow their peanut allergy.
The research, led by Murdoch Children’s Research Institute (MCRI) in Melbourne and published in Allergy, found two thirds of children with a peanut allergy remain allergic by the age of 10. But for those who did naturally outgrow their allergy, the majority achieved this by six years old.
The study was the first to use antibodies as biomarkers to identify persistent or a resolved ...
By Tom Garlinghouse for the Princeton University Department of Physics
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions that give rise to magnetism have been understood for around a century, since the early days of quantum mechanics. But there are many different forms of magnetism in nature, and scientists are still discovering the mechanisms that drive them.
Now, physicists ...
When two animals look the same, eat the same, behave the same way, and live in similar environments, one might expect that they belong to the same species.
However, a tiny zooplankton skimming the ocean surfaces of microscopic food particles challenges this assumption. Researchers from Osaka University, University of Barcelona and the Okinawa Institute of Science and Technology (OIST) have analyzed the genome of Oikopleura dioica from the Seto Inland Sea, the Mediterranean, and the Pacific Ocean around the Okinawa Islands, and in doing so, they have raised numerous questions about speciation and the role of gene location in ...
[Highlights]
- Developed a new compilation method to generate optimal sequences to be executed on quantum computers
- The new method is based on a probabilistic approach and reduces the time to search for the optimal sequence by several orders of magnitude.
- Expected to contribute to quantum information processing at quantum nodes that support the quantum internet
[Abstract]
The National Institute of Information and Communications Technology (NICT, President: TOKUDA Hideyuki, Ph.D.), RIKEN (President: GONOKAMI Makoto, Ph.D.), Tokyo University of Science (President: Dr. ISHIKAWA Masatoshi), and the University of Tokyo (President: FUJII Teruo, Ph.D.) succeeded ...
WASHINGTON— A new analysis of the world’s largest 100 marine protected areas (MPAs) published today in Conservation Letters suggests that governments are falling short on delivering the promise of effective biodiversity protection due to slow implementation of management strategies and failure to restrict the most impactful activities.
The assessment, titled “Ocean protection quality is lagging behind quantity: Applying a scientific framework to assess real marine protected area progress ...
Just a few days on a night shift schedule throws off protein rhythms related to blood glucose regulation, energy metabolism and inflammation, processes that can influence the development of chronic metabolic conditions.
The finding, from a study led by scientists at Washington State University and the Pacific Northwest National Laboratory, provides new clues as to why night shift workers are more prone to diabetes, obesity and other metabolic disorders.
“There are processes tied to the master biological clock in our brain that are saying that day ...
Recently, Nano Research announced awardees of the 11th Nano Research Award. Two outstanding scientists, Professor Louis E. Brus of Columbia University and Professor Moungi Bawendi of Massachusetts Institute of Technology, have been awarded this honor.
The Nano Research Award, established by the journal Nano Research together with Tsinghua University Press (TUP) and Springer Nature in 2013, aims to recognize outstanding contributions to nano research by an individual scientist. The winner is selected by the Award Committee ...
Among New Yorkers with low incomes, the “Vision Zero” initiative to stem roadway crashes resulted in a marked, 30% reduction in traffic injuries of varying severity from early 2014 – when the city government launched the program – until 2019, according to a new study conducted at New York University.
The study, scheduled for publication May 8 at 4:00 p.m. (ET) in the American Journal of Public Health, revealed this trend of improved safety by comparing Medicaid-covered injury ...
Suicidality hit new record high in U.S. in 2022
New tool was 92% effective at predicting four variables related to self-harm
AI uses a small set of judgment and contextual variables as opposed to big data, and strongly supports the hypothesis of a standard model of mind
EVANSTON, Ill. --- A new assessment tool that leverages powerful artificial intelligence was able to predict whether participants exhibited suicidal thoughts and behaviors using a quick and simple combination of variables.
Developed by researchers at Northwestern University, the University of Cincinnati (UC), Aristotle ...
